MiR-145 improves macrophage-mediated inflammation through targeting Arf6

Area of Science:

• Molecular Biology
• Immunology
• Metabolic Disease Research

Background:

• Macrophage-mediated inflammation is a key factor in metabolic diseases.
• MicroRNAs (miRNAs) play crucial roles in regulating cellular processes, including inflammation.
• ADP ribosylation factor 6 (Arf6) is implicated in cellular signaling pathways relevant to inflammation.

Purpose of the Study:

• To investigate the regulatory relationship between miR-145 and Arf6 in the context of macrophage-mediated inflammation.
• To determine if miR-145 influences Arf6 expression and subsequent inflammatory responses.
• To explore the potential of miR-145 as a therapeutic target for metabolic inflammatory conditions.

Main Methods:

• THP-1 cells were differentiated into macrophages and stimulated to mimic chronic metabolic inflammation.
• Dual-luciferase reporter assays were used to confirm direct interaction between miR-145 and Arf6.
• miR-145 and Arf6 expression were modulated using siRNA and RNA interference (RNAi) in vitro.
• Omental adipose tissue from obese and diabetic patients was analyzed for miR-145 and Arf6 expression.

Main Results:

• miR-145 was found to directly down-regulate Arf6 expression.
• Inhibition of miR-145 led to increased Arf6, pro-inflammatory cytokines (IL-1β, TNF-α, IL-6), and NF-κB pathway activation.
• Overexpression of miR-145 reversed these inflammatory effects.
• Down-regulation of Arf6 reduced cytokine production and secretion.
• miR-145 expression was reduced in obese and diabetic patients with higher Arf6 levels.

Conclusions:

• miR-145 inhibits macrophage-mediated inflammation by targeting Arf6 and modulating the NF-κB pathway.
• Reduced miR-145 and elevated Arf6 expression are observed in metabolic disease patient tissues.
• miR-145 holds potential as an anti-inflammatory therapeutic agent for metabolic diseases.